Supernus, Inc., a biopharmaceutical company specializing in central nervous system treatments, announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026. The event offers investors a chance to engage with company management and hear about Supernus's ongoing innovations and business strategies. A live webcast of the presentation will be available on the company's website, with a replay accessible for 60 days after the event. This participation highlights Supernus's commitment to transparency and investor relations as it advances its CNS treatment portfolio and pipeline.
Supernus, Inc.'s upcoming participation in the 2026 Jefferies Global Healthcare Conference in London is noted here with Pluang market data as of Nov 10, 2026 19:42 WIB. For readers following the health sector, 83 of 150 priced US health stocks on Pluang rose while 55 fell. Notable movers include AHCO at USD 7.21 with a 1-day change of -1.90%, SANA at USD 2.42 down 1.83%, and FLNA at USD 0.50 up 1.79%, with FLNA showing the highest sell activity at 88% on Pluang orders.
project44 has partnered with Snowflake to enhance supply chain decision-making through Mo, an AI-powered supply chain analyst. Mo uses project44's extensive logistics data and Snowflake Cortex AI to provide accurate, consistent answers to complex sup...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
